转移性固态肿瘤市场全球市场:类别，各治疗法，各给药途径，各终端用户，各地区，机会，预测，2018年～2032年

全球转移性实体瘤市场规模预计将从2024年的738.6亿美元增长到2032年的1325.8亿美元，在2025-2032年的预测期内，复合年增长率为7.59%。市场的成长归因于癌症发生率的上升、个人化医疗的快速发展以及标靶治疗可及性的增加。美国癌症协会估计，2025年美国将新增超过200万例癌症病例。

此外，早期癌症检测技术、基因编辑技术和基于人工智慧 (AI) 的肿瘤学平台的进步也支撑着市场的成长。有鑑于转移性实体瘤带来的威胁，全球医疗保健产业正在优先考虑肿瘤学领域的投资和创新，为市场创造了有利的成长机会。

本报告提供全球转移性固态肿瘤市场相关调查，提供市场概要，以及类别，各治疗法，各给药途径，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球转移性固态肿瘤市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
  • 类别
    • 肉瘤
    • 癌症肿
    • 淋巴瘤
  • 各治疗法
    • 化疗
    • 免疫疗法
    • 标靶治疗
    • 其他的荷尔蒙疗法及支持疗法
  • 各给药途径
    • 口服
    • 非口服
    • 其他
  • 各终端用户
    • 医院
    • 专门诊所
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
• 2024年的市场地图分析

第6章 北美的转移性固态肿瘤市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
• 各国市场评估
  • 美国
  • 加拿大
  • 墨西哥

第7章 欧洲的转移性固态肿瘤市场预测，2018年～2032年

• 德国
• 法国
• 义大利
• 英国
• 俄罗斯
• 荷兰
• 西班牙
• 土耳其
• 波兰

第8章 亚太地区的转移性固态肿瘤市场预测，2018年～2032年

• 印度
• 中国
• 日本
• 澳洲
• 越南
• 韩国
• 印尼
• 菲律宾

第9章 南美的转移性固态肿瘤市场预测，2018年～2032年

• 巴西
• 阿根廷

第10章 中东·非洲的转移性固态肿瘤市场预测，2018年～2032年

• 沙乌地阿拉伯
• 阿拉伯联合大公国
• 南非

第11章 需求供给分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

• 市场促进因素
• 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

• 法规当局的认证
• 临床试验

第18章 专利的形势

第19章 案例研究

第20章 竞争情形

• 前五名市场领导的竞争矩阵
• 前五名参与企业SWOT分析
• 前10名市场主要企业的形势
  • Viatris Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Novartis AG
  • Amgen Inc.
  • Bayer AG
  • Lupin Limited

第21章 策略性建议

第22章 关于调查公司·免责声明

Global metastatic solid tumors market is projected to witness a CAGR of 7.59% during the forecast period 2025-2032, growing from USD 73.86 billion in 2024 to USD 132.58 billion in 2032. The market's growth can be attributed to the rising prevalence of cancer, rapid advancements in personalized medicines, and increasing accessibility of targeted therapies. The American Cancer Society estimates that over 2 million new cancer cases will be reported in the United States in 2025.

Additionally, the market's growth is also supported by advancements in early cancer detection technologies and gene editing technologies and artificial intelligence (AI)- based oncology platforms. Healthcare sectors across the globe are recognizing the threat posed by metastatic solid tumors and prioritizing investments and innovations in oncology, providing lucrative growth opportunities for the market.

Rising Incidence of Late-Stage Cancer Drive Market Growth

The sharp rise in late-stage cancer diagnoses across the globe is one of the major drivers of the metastatic solid tumors market. A large number of cancer cases are diagnosed at an advanced stage, where curative treatment options are limited. This has led to increased demand for therapies that manage disease progression and prolong survival. Improved diagnostic imaging, liquid biopsies, and biomarker testing are enabling earlier detection of metastasis, allowing for timely treatment interventions. As awareness campaigns expand and cancer screening becomes more widespread in developed nations, early diagnosis rates are improving and fueling the demand for robust therapeutic options such as immune checkpoint inhibitors, tyrosine kinase inhibitors, and PARP inhibitors. Furthermore, the emotional and economic toll of metastatic disease on families has heightened pressure on healthcare systems and pharmaceutical companies to develop novel, cost-effective therapies. As a result, investment in translational oncology research and precision drug development is intensifying. For instance, in December 2024, Daiichi Sankyo Company, Limited presented its clinical research across its oncology portfolio at the San Antonio Breast Cancer Symposium, the 2024 ESMO Asia, and the American Society of Hematology. The company's therapies showed advancements in previously treated HER2 positive metastatic breast cancer.

Technological Advancements Support Market Expansion

Technological advancements are enabling the availability of novel treatment solutions and early detection of metastatic solid tumors with the help of genomic testing. Next generation sequencing and biomarker driven therapies are allowing medical professionals to tailor their treatments on the basis of the patient's unique genetic profile, ensuring minimal side effects and improvements in treatment outcomes. Leading pharmaceutical companies and research organizations across the globe are working on introducing new technologies and therapeutic solutions to effectively treat different metastatic solid tumors. For instance, in August 2024, the United States Food and Drug Administration (FDA) provide accelerated approval to the first engineered cell therapy for a solid tumor, afamitresgene autoleucel (afami-cel, Tecelra). Such breakthroughs and approvals are expected to encourage further investments in clinical adoption and research activities associated with advanced cell therapies, allowing the key players to deliver advanced therapeutic solutions and provide lucrative growth opportunities for the market.

Targeted Therapy Accounts for Significant Share of the Market

The segment's expansion can be attributed to the various advantages associated with the utilization of targeted therapies. Unlike chemotherapy, which indiscriminately affects healthy and cancerous cells, targeted therapies block specific molecular pathways involved in tumor growth and spread. The rising adoption of next-generation sequencing and biomarker-guided treatment strategies has expanded the eligible patient population for targeted agents. These therapies are often used in first- or second-line treatment of metastatic tumors and show improved efficacy and tolerability. Furthermore, the entry of biosimilars and generics for key targeted therapies is increasing their accessibility. As the requirement for personalized treatment regimens increases, the demand for targeted therapies is expected to increase, providing lucrative growth opportunities for the market. Thus, leading pharmaceutical companies across the globe are focusing on launching new therapies and regulatory bodies are ensuring that they receive accelerated approvals. For instance, in March 2025, China's National Medical Products Administration (NMPA) approved Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's SKB107, an (Radionuclide Drug Conjugate) RDC that targets bone metastases in solid tumors.

North America Holds Major Market Share

The region's dominance can be attributed to the strong presence of leading pharmaceutical companies, increasing investments in the oncology segment, rising focus on research and development activities, and growing threat of cancer in countries such as the United States and Canada. As per the estimates of the Canadian Cancer Society, 2 in 5 Canadians are expected to be diagnosed with cancer during their lifetime. Additionally, regulatory bodies such as the FDA have established accelerated approval pathways for therapies that target metastatic solid tumors, resulting in increasing entry of novel therapeutic solutions. Furthermore, Canada's healthcare system is also focusing on increasing investments towards precision diagnostics and oncology services, providing lucrative growth opportunities for the market. The combination of regulatory support, high awareness among the public about cancer and the various treatment options available, and technological innovations are supporting the market's expansion in North America.

Impact of the U.S. Tariff on Global Metastatic Solid Tumors Market

The recently imposed tariffs are expected to significantly impact on the market as it relies heavily upon international collaborations and complex supply chains. In order to limit the potential impact of the tariffs, leading pharmaceutical companies are focusing on diversification of their supply chains and expansion of their domestic production capacity. However, such measures will require considerable investment and time and will not be able to provide immediate relief from the impact of the tariffs. Due to the disruptions in supply chains, the availability of treatments for metastatic solid tumors is expected to decrease, resulting in increased treatment costs and unavailability of essential cancer therapies for economically weaker patient population.

Key Players Landscape and Outlook

The key players of the market are focusing on research and development activities and product innovations to bolster the availability of new therapeutic solutions and expand their presence in the market. For instance, in April 2024, AstraZeneca PLC's and Daiichi Sankyo Company, Limited's ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the United States for treating adults with metastatic or unresectable HER2-positive solid tumors that have received systemic treatment but haven't received satisfactory outcomes. The approval was granted after the drug secured the breakthrough therapy designation in the United States and was provided under their real-time oncology review program. Such approvals are incentivizing the key players of the market to invest in research and development activities and positively influencing the market's expansion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Metastatic Solid Tumors Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Sarcomas
    • 5.2.1.2. Carcinomas
    • 5.2.1.3. Lymphomas
  • 5.2.2. By Treatment
    • 5.2.2.1. Chemotherapy
      • 5.2.2.1.1. Platinum-based Drugs
      • 5.2.2.1.2. Taxanes
      • 5.2.2.1.3. Anthracyclines
      • 5.2.2.1.4. Others
    • 5.2.2.2. Immunotherapy
    • 5.2.2.3. Targeted Therapy
      • 5.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
      • 5.2.2.3.2. Monoclonal Antibodies
      • 5.2.2.3.3. Others
    • 5.2.2.4. Other Hormonal and Supportive Care
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Oral
    • 5.2.3.2. Parenteral
    • 5.2.3.3. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Hospitals
    • 5.2.4.2. Specialty Clinics
    • 5.2.4.3. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Type
  • 5.3.2. By Treatment
  • 5.3.3. By Route of Administration
  • 5.3.4. By End-user
  • 5.3.5. By Region

6. North America Metastatic Solid Tumors Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Type
    • 6.2.1.1. Sarcomas
    • 6.2.1.2. Carcinomas
    • 6.2.1.3. Lymphomas
  • 6.2.2. By Treatment
    • 6.2.2.1. Chemotherapy
      • 6.2.2.1.1. Platinum-based Drugs
      • 6.2.2.1.2. Taxanes
      • 6.2.2.1.3. Anthracyclines
      • 6.2.2.1.4. Others
    • 6.2.2.2. Immunotherapy
    • 6.2.2.3. Targeted Therapy
      • 6.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
      • 6.2.2.3.2. Monoclonal Antibodies
      • 6.2.2.3.3. Others
    • 6.2.2.4. Other Hormonal and Supportive Care
  • 6.2.3. By Route of Administration
    • 6.2.3.1. Oral
    • 6.2.3.2. Parenteral
    • 6.2.3.3. Others
  • 6.2.4. By End-user
    • 6.2.4.1. Hospitals
    • 6.2.4.2. Specialty Clinics
    • 6.2.4.3. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Metastatic Solid Tumors Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Type
        • 6.3.1.2.1.1. Sarcomas
        • 6.3.1.2.1.2. Carcinomas
        • 6.3.1.2.1.3. Lymphomas
      • 6.3.1.2.2. By Treatment
        • 6.3.1.2.2.1. Chemotherapy
        • 6.3.1.2.2.1.1. Platinum-based Drugs
        • 6.3.1.2.2.1.2. Taxanes
        • 6.3.1.2.2.1.3. Anthracyclines
        • 6.3.1.2.2.1.4. Others
        • 6.3.1.2.2.2. Immunotherapy
        • 6.3.1.2.2.3. Targeted Therapy
        • 6.3.1.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
        • 6.3.1.2.2.3.2. Monoclonal Antibodies
        • 6.3.1.2.2.3.3. Others
        • 6.3.1.2.2.4. Other Hormonal and Supportive Care
      • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.3.1. Oral
        • 6.3.1.2.3.2. Parenteral
        • 6.3.1.2.3.3. Others
      • 6.3.1.2.4. By End-user
        • 6.3.1.2.4.1. Hospitals
        • 6.3.1.2.4.2. Specialty Clinics
        • 6.3.1.2.4.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Metastatic Solid Tumors Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Metastatic Solid Tumors Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Metastatic Solid Tumors Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Metastatic Solid Tumors Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals
• 17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Viatris Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. F. Hoffmann-La Roche Ltd
  • 20.3.3. AstraZeneca PLC
  • 20.3.4. AbbVie Inc.
  • 20.3.5. Eli Lilly and Company
  • 20.3.6. GlaxoSmithKline plc
  • 20.3.7. Novartis AG
  • 20.3.8. Amgen Inc.
  • 20.3.9. Bayer AG
  • 20.3.10. Lupin Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 3. Global Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 4. Global Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 5. Global Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 6. Global Metastatic Solid Tumors Market Share (%), By Region, 2018-2032F
• Figure 7. North America Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 9. North America Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 10. North America Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 11. North America Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 12. North America Metastatic Solid Tumors Market Share (%), By Country, 2018-2032F
• Figure 13. United States Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 15. United States Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 16. United States Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 17. United States Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 18. Canada Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 20. Canada Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 21. Canada Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Canada Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 23. Mexico Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 25. Mexico Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 26. Mexico Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 27. Mexico Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 28. Europe Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 30. Europe Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 31. Europe Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 32. Europe Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 33. Europe Metastatic Solid Tumors Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 36. Germany Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 37. Germany Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 38. Germany Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 39. France Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 41. France Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 42. France Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. France Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 44. Italy Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 46. Italy Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 47. Italy Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 48. Italy Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 49. United Kingdom Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 51. United Kingdom Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 52. United Kingdom Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 53. United Kingdom Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 54. Russia Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 56. Russia Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 57. Russia Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 58. Russia Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 59. Netherlands Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 61. Netherlands Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 62. Netherlands Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Netherlands Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 64. Spain Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 66. Spain Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 67. Spain Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 68. Spain Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 69. Turkey Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 71. Turkey Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 72. Turkey Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 73. Turkey Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 74. Poland Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 76. Poland Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 77. Poland Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 78. Poland Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 79. South America Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 81. South America Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 82. South America Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 83. South America Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 84. South America Metastatic Solid Tumors Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 87. Brazil Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 88. Brazil Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 89. Brazil Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 90. Argentina Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 92. Argentina Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 93. Argentina Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 94. Argentina Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 95. Asia-Pacific Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 97. Asia-Pacific Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 98. Asia-Pacific Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 99. Asia-Pacific Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 100. Asia-Pacific Metastatic Solid Tumors Market Share (%), By Country, 2018-2032F
• Figure 101. India Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 103. India Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 104. India Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 105. India Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 106. China Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 108. China Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 109. China Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 110. China Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 111. Japan Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 113. Japan Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 114. Japan Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 115. Japan Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 116. Australia Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 118. Australia Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 119. Australia Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 120. Australia Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 121. Vietnam Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 123. Vietnam Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 124. Vietnam Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 125. Vietnam Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 126. South Korea Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 128. South Korea Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 129. South Korea Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Korea Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 131. Indonesia Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 133. Indonesia Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 134. Indonesia Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 135. Indonesia Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 136. Philippines Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 138. Philippines Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 139. Philippines Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 140. Philippines Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 141. Middle East & Africa Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 143. Middle East & Africa Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 144. Middle East & Africa Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 145. Middle East & Africa Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 146. Middle East & Africa Metastatic Solid Tumors Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 149. Saudi Arabia Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 150. Saudi Arabia Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 151. Saudi Arabia Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 152. UAE Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 154. UAE Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 155. UAE Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 156. UAE Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 157. South Africa Metastatic Solid Tumors Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Metastatic Solid Tumors Market Share (%), By Type, 2018-2032F
• Figure 159. South Africa Metastatic Solid Tumors Market Share (%), By Treatment, 2018-2032F
• Figure 160. South Africa Metastatic Solid Tumors Market Share (%), By Route of Administration, 2018-2032F
• Figure 161. South Africa Metastatic Solid Tumors Market Share (%), By End-user, 2018-2032F
• Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024